Abstract
Background Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, with acute myocardial infarction (AMI) contributing to over 100,000 deaths annually in the United States. Accurate risk stratification for in-hospital mortality is essential for guiding clinical decisions, improving outcomes, and optimizing hospital resources. However, existing models often rely on limited predictor sets, outdated data, and linear methods that may not reflect current clinical practice or complex interactions.
Objective To develop and validate a contemporary in-hospital mortality risk model for AMI patients using modern statistical and machine learning approaches, incorporating clinical, demographic, and social determinants of health.
Methods We utilized data from the American Heart Association (AHA) Get with The Guidelines®– Coronary Artery Disease (GWTG-CAD) Registry. Patients with AMI admitted between October 1, 2019, and December 31, 2022 (201,191 patients from 605 hospitals) were used to develop the in-hospital mortality prediction model. An independent validation cohort included 70,302 patients admitted in 2023. We incorporated 27 predictors, including demographics, comorbidities, vital signs, laboratory values, and social determinants of health. We assessed the models including a generalized linear mixed model (GLMM) and machine learning algorithms. We benchmarked against the legacy ACTION Registry–GWTG model. Subgroup and sensitivity analyses assessed model performance across sex, race/ethnicity, STEMI status, and time period.
Results The LightGBM-based GWTG-CAD model achieved the highest discrimination (AUROC 0.874, 95% CI: 0.867–0.880) and demonstrated excellent calibration across all subgroups. Both GLMM and LightGBM outperformed the ACTION Registry–GWTG model, with LightGBM showing the most consistent performance in the 2023 validation cohort. Beyond traditional predictors, the inclusion of comorbidities, transportation methods, and community-level socioeconomic factors added predictive value.
Conclusion The new GWTG-CAD risk model incorporates clinical, pre-hospital, and social factor predictors, along with machine learning methods, to enhance prediction of mortality in contemporary AMI patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Because data are used primarily at the local site for quality improvement, each participating hospital received either human research approval to enroll cases without individual patient consent under the Common Rule, or a waiver of authorization and exemption from subsequent review by their institutional review board (IRB). Advarra, the IRB for the American Heart Association, determined that this study is exempt from IRB oversight. The data collection and coordination for GWTG programs are managed by IQVIA (Parsippany, New Jersey).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The Precision Medicine Platform is a cloud-based system that allows researchers to collaborate and analyze large datasets from any computer in the world using a secure environment and the power of machine learning. Within the research interface, users have access to assorted datasets, including the industry-changing Get With The Guidelines® registry data to accelerate findings into impactful discoveries. Researchers must have an approved research proposal to access Get With The Guidelines® registry data.
